Role of early circulating tumour cell (CTC) monitoring for prediction of clinical outcome in patients with HER-2 negative metastatic breast cancer receiving first-line treatment with bevacizumab and paclitaxel

Alvarez-Lopez, I.Gonzalez, E.Manso, L. M.Alonso, J. L.Cruz-Hernandez, J. J.Caranana Ballerini, V.Gallegos, I.Quindos Varela, M.Illaramendi, J. J.Vicente, E.Ballesteros Garcia, A. I.Ayala de la Pena, F.Perello, A.Vidal, J.Llombart Cussac, A.2025-01-072025-01-072020-05-010923-7534https://hdl.handle.net/10668/26246enRole of early circulating tumour cell (CTC) monitoring for prediction of clinical outcome in patients with HER-2 negative metastatic breast cancer receiving first-line treatment with bevacizumab and paclitaxelconference outputopen access10.1016/j.annonc.2020.03.1731569-8041http://www.annalsofoncology.org/article/S0923753420362529/pdf538879300035